References
- 1. B. P. Kersten and M. E. McLaughlin, Toxicology and management of novel psychoactive drugs, J. Pharm.28 (2015) 50–65; https://doi.org/10.1177/0897190014544814
- 2. D. P. Katz, J. Deruiter, D. Bhattacharya, M. Ahuja, S. Bhattacharya and C. R. Clark, Benzylpiperazine: “A messy drug”, Drug Alc. Dep.164 (2016) 1–7; https://doi.org/10.1016/j.drugalcdep.2016.04.010
- 3. A. Kwiatkowska and W. Lewicka, New psychoactive substances and risky sexual behaviors: chemsex, teensex, slamsex, Świat Probl. (World of Problems)309 (2018) 7–10.
- 4. F. Schifano, L. Orsolini, G. D. Papanti and J. M. Corkery, Novel psychoactive substances of interest for psychiatry, World Psych.14 (2015) 15–26; https://doi.org/10.1002/wps.20174
- 5. Y. Boumrah, M. Rosset, Y. Lecompte, S. Bouanani, K. Khimeche and A. Dahmani, Development of a targeted GC/MS screening method and validation of an HPLC/DAD quantification method for piperazines-amphetamines mixtures in seized material, Egypt. J. For. Sci.4 (2014) 90–99; https://doi.org/10.1016/j.ejfs.2014.03.002
- 6. C. D. Rosenbaum, S. P. Carreiro and K. M. Babu, Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines, J. Med. Toxicol.8 (2012) 15–32; https://doi.org/10.1007/s13181-011-0202-2
- 7. M. D. Arbo, M. L. Bastos and H. F. Carmo, Piperazine compounds as drugs of abuse, Drug Alc. Dep.122 (2012) 174–185; https://doi.org/10.1016/j.drugalcdep.2011.10.007
- 8. Y. P. Gaillard, A. C. Cuquel, A. Boucher, L. Romeuf, F. Bevalot, J. M. Prevosto and J. M. Menard, A fatality following ingestion of the designer drug meta-chlorophenylpiperazine (mCPP) in an asthmatic – HPLC-MS/MS detection in biofluids and hair, J. For. Sci.58 (2013) 263–269; https://doi.org/10.1111/j.1556-4029.2012.02254.x
- 9. D. De Berardis, G. Rapini, L. Olivieri, D. Di Nicola, C. Tomasetti, A. Valchera, M. Fornaro, F. Di Fabio, G. Perna, M. Di Nicola, G. Serafini, A. Carano, M. Pompili, F. Vellante, L. Orsolini, G. Martinotti and M. Di Giannantonio, Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine, Ther. Adv. Drug Saf.9 (2018) 237–256; https://doi.org/10.1177/2042098618756261
- 10. A. Pouliopoulos, E. Tsakelidou, A. Krokos, H. G. Gika, G. Theodoridis and N. Raikos, Quantification of 15 psychotropic drugs in serum and postmortem blood samples after a modified mini-QuEChERS by UHPLC–MS-MS, J. Anal. Toxicol.42 (2018) 337–345; https://doi.org/10.1093/jat/bky006
- 11. U. Hariharan, M. Hariharan, J. S. Naickar and R. Tandon, Determination of clozapine and its two major metabolites in human serum by liquid chromatography using ultraviolet detection, J. Liq. Chrom. Rel. Technol.19 (1996) 2409–2417; https://doi.org/10.1080/10826079608014026
- 12. M. Pogorzała, J. Styczyński, K. Jankowska, A. Kurylak and M. Wysocki, Imatinib mesylate in treatment of childhood chronic myeloid leukaemia. Preliminary report, Med. W. Rozwoj. (Developmental Period Medicine) 10 (2006) 603–612.
- 13. A. Wojnicz, B. Colom-Fernández, J. L. Steegmann, C. Muñoz-Calleja, F. Abad-Santos and A. RuizNuño, Simultaneous Determination of imatinib, dasatinib, and nilotinib by liquid chromatographytandem mass spectrometry and its application to therapeutic drug monitoring, Ther. Drug Monit.39 (2017) 252–262; https://doi.org/10.1097/FTD.0000000000000406
- 14. M. Gackowski, M. Koba, K. Mądra-Gackowska and S. Kruszewski, Comparison of high-performance thin layer chromatography/UV-densitometry and UV-derivative spectrophotometry for the determination of trimetazidine in pharmaceutical formulations, Acta Pharm.69 (2019) 413–422; https://doi.org/10.2478/acph-2019-0028
- 15. L. Wang, Y. Zhang, X. Du, T. Ding, W. Gong and F. Liu, Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors, Biomed. Pharmacother.120 (2019) 1–9; https://doi.org/10.1016/j.biopha.2019.109408
- 16. D. M. Wood, L. De La Rue, A. A. Hosin, G. Jurgens, E. Liakoni, F. Heyerdahl, K. E. Hovda, A. Dines, I. Giraudon, M. E. Liechti and P. I. Dargan, Poor identification of emergency department acute recreational drug toxicity presentations using routine hospital coding systems: the experience in Denmark, Switzerland and the UK, J. Med. Toxicol.15 (2019) 112–120; https://doi.org/10.1007/s13181-018-0687-z
- 17. M. S. Monteiro, M. de Lourdes Bastos, P. Guedes de Pinho and M. Carvalho, Update on 1-benzylpiperazine (BZP) party pills, Arch. Toxicol. 87 (2013) 929–947; https://doi.org/10.1007/s00204-013-1057-x
- 18. Y. Ren, J. Du, X. Du, G. Xin, J. Chang, H. Zhou and H. Hao, A novel analytical method of TFMPP and mCPP in fluids of drug addicts using LLE-GC/NPD, Tech. Health Care27 (2019) 67–84; https://doi.org/10.3233/THC-199008
- 19. M. S. Castaneto, A. J. Barnes, M. Concheiro, K. L. Klette, T. A. Martin and M. A. Huestis, Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing, Anal. Bioanal. Chem. 407 (2015) 4639–4648; https://doi.org/10.1007/s00216-015-8660-z
- 20. D. Zuba, B. Byrska, P. Pytka, K. Sekuła and R. Stanaszek, Mass Spectra of the Active Ingredients of Preparations of Designer Drugs (original title: Widma masowe składników aktywnych preparatów typu dopalacze), Institute of Forensic Research Publishers, Kraków 2011, pp. 197–221.
- 21. K. Persona, A. Polus, J. Góralska, A. Gruca, A. Dembińska-Kieć and W. Piekoszewski, An in vitro study of the neurotoxic effects of N-benzylpiperazine: a designer drug of abuse, Neurotox. Res.29 (2016) 558–568; https://doi.org/10.1007/s12640-016-9604-x
- 22. A. Zwartsen, L. Hondebrink and R. H. Westerink, Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA), NeuroTox.66 (2018) 87–97; https://doi.org/10.1016/j.neuro.2018.03.007
- 23. A. Welz and M. Koba, Piperazine derivatives in designer drugs – compounds of great popularity and high risk for human health, Farm. Pol. 73 (2017) 487–494.
- 24. D. Dias da Silva, M. J. Silva, P. Moreira, M. J. Martins, M. J. Valente, F. Carvalho, M. L. Bastos and H. Carmo, In vitro hepatotoxicity of ‘Legal X’: the combination of 1-benzylpiperazine (BZP) and 1-(mtrifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis, Arch. Toxicol. 91 (2017) 1413–1430; https://doi.org/10.1007/s00204-016-1777-9
- 25. D. M. Wood, J. Button, S. Lidder, J. Ramsey, D. W. Holt and P. I. Dargan, Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and 1-benzylpiperazine (BZP), J. Med. Toxicol.4 (2008) 254–257; https://doi.org/10.1007/bf03161209
- 26. M. E. Musselman and J. P. Hampton, “Not for human consumption”: A review of emerging designer drugs, Pharmacotherapy 34 (2014) 745–757; https://doi.org/10.1002/phar.1424
- 27. B. M. Cohen and R. Butler, BZP-party pills: A review of research on benzylpiperazine as a recreational drug, Int. J. Drug Policy22 (2011) 95–101; https://doi.org/10.1016/j.drugpo.2010.12.002
- 28. H. Lee, G. Y. Wang, L. E. Curley, J. J. Sollers, R. R. Kydd, I. J. Kirk and B. R. Russell, Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study, Psychopharmacology (Berlin) 233 (2016) 863–871; https://doi.org/10.1007/s00213-015-4165-x
- 29. M. G. Fitzsimons, Y. Ishizawa and K. H. Baker, Drug testing physicians for substances of abuse: case report of false-positive result, J. Clin. Anesth. 25 (2013) 669–671; https://doi.org/10.1016/j.jclinane.2013.05.009
- 30. J. Jaroszyński, M. Roszkowska and H. Plata, Designer drugs – a threat whether already plague? Part 1, Farm. Pol. 72 (2016) 342–347.
- 31. S. W. Tang and W. H. Tang, Opportunities in novel psychotropic drug design from natural compounds, Int. J. Neuropsychopharmacol.22 (2019) 601–607; https://doi.org/10.1093/ijnp/pyz042
- 32. European Monitoring Centre for Drugs and Drug Addiction, European Drug Report: Trends and Developments – 2017, EMCDDA, Publications Office of the European Union, Luxembourg 2017, pp. 34; http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf
- 33. F. Schifano, Recent changes in drug abuse scenarios: The new/novel psychoactive substances (NPS) phenomenon, Brain Sci.8 (2018) 1–3; https://doi.org/10.3390/brainsci8120221
- 34. E. Wadsworth, C. Drummond and P. Deluca, The dynamic environment of crypto markets: The lifespan of new psychoactive substances (NPS) and vendors selling NPS, Brain Sci.8 (2018) 1–9; https://doi.org/10.3390/brainsci8030046
- 35. J. Neicun, M. Steenhuizen, R. van Kessel, J. C. Yang, A. Negri, K. Czabanowska, O. Corazza and A. Roman-Urrestarazu, Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden, Plos One14 (2019) 1–29; https://doi.org/10.1371/journal.pone.0218011
- 36. C. Görgens, S. Guddat, A. K. Orlovius, G. Sigmund, A. Thomas, M. Thevis and W. Schänzer, “Diluteand-inject” multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing, Anal. Bioanal. Chem. 407 (2015) 5365–5379; https://doi.org/10.1007/s00216-015-8699-x
- 37. C. Wilkins and P. Sweetsur, The impact of the prohibition of benzylpiperazine ( BZP ) ‘legal highs’ on the prevalence of BZP, new legal highs and other drug use in New Zealand, Drug Alc. Dep. 127 (2013) 72–80; https://doi.org/10.1016/j.drugalcdep.2014.07.011
- 38. L. Hondebrink, A. Zwartsen and R. H. S. Westerink, Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? Pharmacol. Ther. 182 (2018) 193–224; https://doi.org/10.1016/j.pharmthera.2017.10.022
- 39. A. Zwartsen, C. H. C. Litjens, L. Hondebrink, J. J. M. W. van den Heuvel, R. Greupink, F. G. M. Russel, D. W. de Lange, J. Legler, J. B. Koenderink and R. H. S. Westerink, Differential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT), Toxicology422 (2019) 69–75; https://doi.org/10.1016/j.tox.2019.04.012
- 40. M. A. Sahai, C. Davidson, N. Dutta and J. Opacka-Juffry, mechanistic insights into the stimulant properties of novel psychoactive substances (NPS) and their discrimination by the dopamine transporter-in silico and in vitro exploration of dissociative diarylethylamines, Brain Sci.8 (2018) 1–19; https://doi.org/10.3390/brainsci8040063
- 41. W. J. Scotton, L. J. Hill, A. C. Williams and N. M. Barnes, Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions, Int. J. Tryptophan Res.12 (2019) 1–14; https://doi.org/10.1177/1178646919873925
- 42. A. C. Parrott, Mood fluctuation and psychobiological instability: The same core functions are disrupted by novel psychoactive substances and established recreational drugs, Brain Sci.8 (2018) 43; https://doi.org/10.3390/brainsci8030043
- 43. C. D. Smith and S. Robert, ‘Designer drugs’: update on the management of novel psychoactive substance misuse in the acute care setting, Clin. Med. 14 (2014) 409–415; https://doi.org/10.7861/clinmedicine.14-4-409
- 44. L. Orsolini, G. D. Papanti, D. De Berardis, A. Guirguis, J. M. Corkery and F. Schifano, The “Endless trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review, Front. Psychiatry8 (2017) 1–10; https://doi.org/10.3389/fpsyt.2017.00240
- 45. J. M. Thomas, C. T. Dourish, J. Tomlinson, Z. Hassan-Smith, P. C. Hansen and S. Higgs, The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers, Psychopharmacology235 (2018) 257–267; https://doi.org/10.1007/s00213-017-4764-9
- 46. D. E. Felsing, C. E. Canal and R. G. Booth, Ligand-directed serotonin 5-HT2C receptor desensitization and sensitization, Eur. J. Pharmacol.848 (2019) 131–139 https://doi.org/10.1016/j.ejphar.2019.01.037
- 47. L. D. Simmler, A. Rickli, Y. Schramm, M. C. Hoener and M. E. Liechti, Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives, Biochem. Pharmacol. 88 (2014) 237–244; https://doi.org/10.1016/j.bcp.2014.01.024
- 48. D. Luethi and M. E. Liechti, Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics, Int. J. Neuropsychopharmacol.21 (2018) 926–931; https://doi.org/10.1093/ijnp/pyy047
- 49. K. T. Kirla, K. J. Groh, M. Poetzsch, R. K. Banote, J. Stadnicka-Michalak, R. I. L. Eggen, K. Schirmer and T. Kraemer, Importance of toxicokinetics to assess the utility of zebrafish larvae as model for psychoactive drug screening using meta-chlorophenylpiperazine (mCPP) as example, Front. Pharmacol.9 (2018) 1–12; https://doi.org/10.3389/fphar.2018.00414
- 50. M. D. Arbo, R. Silva, D. J. Barbosa, D. D. Dias da Silva, L. G. Rossato, Mde L. Bastos and H. Carmo, Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment, Toxicol. Lett. 229 (2014) 178–189; https://doi.org/10.1016/j.toxlet.2014.06.031
- 51. G. Repetto, A. del Peso and J. L. Zurita, Neutral red uptake assay for the estimation of cell viability/cytotoxicity, Nat. Protoc. 3 (2008) 1125–1131; https://doi.org/10.1038/nprot.2008.75
- 52. A. Zwartsen, T. de Korte, P. Nacken, D. W. de Lange, R. H. S. Westerink and L. Hondebrink, Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings, J. Mol. Cell. Cardiol.136 (2019) 102–112; https://doi.org/10.1016/j.yjmcc.2019.09.007
- 53. L. E. Curley, R. R. Kydd, I. J. Kirk and B. R. Russell, Differential responses to anticipation of reward after an acute dose of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) alone and in combination using functional magnetic resonance imaging (fMRI), Psychopharmacology229 (2013) 673–685; https://doi.org/10.1007/s00213-013-3128-3
- 54. T. Misiuro and Ł. Nikel, Event-related Potentials in Studies of Deception Detection, in Studies of Psychology in KUL, Publishing House of Catholic University of Lublin, Lublin 2012, Vol. 18, pp. 217–232.
- 55. D. Dias-da-Silva, M. D. Arbo, M. J. Valente, M. L. Bastos and H. Carmo, Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models, Toxicol. In Vitro29 (2015) 987–996; https://doi.org/10.1016/j.tiv.2015.04.001
- 56. C. Gu, C. S Elmore, J. Lin, D. Zhou, R. Luzietti, P. Dorff and S. W. Grimm, Metabolism of a G proteincoupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct, Drug Metab. Dispos.40 (2012) 1151–1163; https://doi.org/10.1124/dmd.112.044636
- 57. C. R. Min, M. J. Kim, Y. J. Park, H. R. Kim, S. Y. Lee, K. H. Chung and S. M. Oh, Estrogenic effects and their action mechanism of the major active components of party pill drugs, Toxicol. Lett.214 (2012) 339–347; https://doi.org/10.1016/j.toxlet.2012.09.014
- 58. M. J. Swortwood, D. M. Boland and A. P. DeCaprio, Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis, Anal. Bioanal. Chem. 405 (2013) 1383–1397; https://doi.org/10.1007/s00216-012-6548-8
- 59. M. Tang, C. K. Ching, M. L. Tse, C. Ng, C. Lee, Y. K. Chong, W. Wong and T. W. Mak, Surveillance of emerging drugs of abuse in Hong Kong: validation of an analytical tool, Hong Kong Med. J. 21 (2015) 114–123; https://doi.org/10.12809/hkmj144398
- 60. M. Paul, J. Ippisch, C. Herrmann, S. Guber and W. Schultis, Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach, Anal. Bioanal. Chem. 406 (2014) 4425–4441; https://doi.org/10.1007/s00216-014-7825-5
- 61. M. Concheiro, M. Castaneto, R. Kronstrand and M. A. Huestis, Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching, J. Chromatogr. A1397 (2015) 32–42; https://doi.org/10.1016/j.chroma.2015.04.002
- 62. A. J. Dickson, S. P. Vorce, J. M. Holler and T. P. Lyons, Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples, J. Anal. Toxicol. 34 (2010) 464–469; https://doi.org/10.1093/jat/34.8.464
- 63. B. Byrska, D. Zuba and R. Stanaszek, Determination of piperazine derivatives in “legal highs”, Probl. Forensic Sci. 81 (2010) 101–113; http://www.forensicscience.pl/pfs/81_byrska.pdf
- 64. N. M. Beckett, S. L. Cresswell, D. I. Grice and J. F. Carter, Isotopic profiling of seized benzylpiperazine and trifluoromethylphenylpiperazine tablets using δ13C and δ15N stable isotopes, Sci. Justice55 (2015) 51–56; https://doi.org/10.1016/j.scijus.2014.08.003
- 65. J. DeRuiter, A. Van Cleave, A. de Sousa Moura, Y. Abiedalla and C. R. Clark, Disubstituted piperazine analogues of trifluoromethylphenylpiperazine and methylenedioxybenzylpiperazine: analytical differentiation and serotonin receptor binding studies, Forensic Sci. Res.3 (2018) 161–169; https://doi.org/10.1080/20961790.2018.1445497
- 66. C. Guillou, F. Reniero, J. Lobo Vicente, M. Holland, K. Kolar, H. Chassaigne, S. Tirendi and H. Schepers, Collaboration of the joint research centre and European customs laboratories for the identification of new psychoactive substances, Curr. Pharm. Biotechnol.19 (2018) 91–98; https://doi.org/10.2174/1389201019666180523122717
- 67. R. J. Waite, G. J. Barbante, N. W. Barnett, E. M. Zammit and P. S. Francis, Chemiluminescence detection of piperazine designer drugs and related compounds using tris(2,2′-bipyridine)ruthenium(III), Talanta116 (2013) 1067–1072; https://doi.org/10.1016/j.talanta.2013.08.029
- 68. K. A. Kovar and M. Laudszun, Chemistry and reaction mechanisms of rapid tests for drugs of abuse and precursors chemicals, United Nations – Scientific and Technical Notes – SCITEC/6, February 1989, Vol. 89-51669, pp. 1–19; https://mafiadoc.com/chemistry-and-reaction-mechanisms-of-rapidtests_5a1f0c171723dd457b42455f.html
- 69. L. Elie, M. Baron, R. Croxton and M. Elie, Microcrystalline identification of selected designer drugs, Forensic Sci. Int. 214 (2012) 182–188; https://doi.org/10.1016/j.forsciint.2011.08.005
- 70. M. Philp, R. Shimmon, N. Stojanovska, M. Tahtouh and S. Fu, Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials, Anal. Meth. 5 (2013) 5402–5410; https://doi.org/10.1039/c3ay40511g
- 71. S. A. Waddell, C. Fernandez, C. C. Inverarity and R. Prabhu, Extending the capability of forensic electrochemistry to the novel psychoactive substance benzylpiperazine, Sens. Bio-Sens. Res. 13 (2017) 28–39.
- 72. S. C. Bishop, B. R. McCord, S. R. Gratz, J. R. Loeliger and M. R. Witkowski, Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector, J. Forensic Sci. 50 (2005) 1–10; https://doi.org/10.1520/JFS2004239
- 73. P. D. Maskell, L. N. Seetohul, A. C. Livingstone, A. K. Cockburn, J. Preece and D. J. Pounder, Stability of 3,4-methylenedioxymethampetamine (MDMA), 4-methylmethcathinone (mephedrone) and 3-tri-fluoromethylphenylpiperazine (3-TFMPP) in formalin solution, J. Anal. Toxicol.37 (2013) 440–446; https://doi.org/10.1093/jat/bkt051
- 74. D. S. Wenholz, S. Luong, M. Philp, S. L. Forbes, B. H. Stuart, O. H. Drummer and S. Fu, A study to model the post-mortem stability of 4-MMC, MDMA and BZP in putrefying remains, For. Sci. Int.265 (2016) 54–60; https://doi.org/10.1016/j.forsciint.2016.01.006
- 75. R. D. Johnson and S. R. Botch-Jones, The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in three biological matrices under various storage conditions, J. Anal. Toxicol.37 (2013) 51–55; https://doi.org/10.1093/jat/bks138
- 76. T. Lau, R. LeBlanc and S. Botch-Jones, Stability of synthetic piperazines in human whole blood, J. Anal. Toxicol.42 (2018) 88–98; https://doi.org/10.1093/jat/bkx090
Language: English
Page range: 423 - 441
Accepted on: Dec 3, 2019
Published on: May 13, 2020
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2020 Anna Welz, Marcin Koba, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.